HUP0400668A2 - A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére - Google Patents

A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére

Info

Publication number
HUP0400668A2
HUP0400668A2 HU0400668A HUP0400668A HUP0400668A2 HU P0400668 A2 HUP0400668 A2 HU P0400668A2 HU 0400668 A HU0400668 A HU 0400668A HU P0400668 A HUP0400668 A HU P0400668A HU P0400668 A2 HUP0400668 A2 HU P0400668A2
Authority
HU
Hungary
Prior art keywords
histone deacetylase
deacetylase inhibitor
antitumor effect
medicinal use
evaluating
Prior art date
Application number
HU0400668A
Other languages
English (en)
Inventor
Yuka Sasakawa
Yoshinori Naoe
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of HUP0400668A2 publication Critical patent/HUP0400668A2/hu
Publication of HUP0400668A3 publication Critical patent/HUP0400668A3/hu
Publication of HU229521B1 publication Critical patent/HU229521B1/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

A találmány tárgyát prosztatarák elleni terápiás ágens, valamintrosszindulatú limfóma (a T-sejtes limfóma kivételével) elleni terápiáságens képezi, ami FK228-ta, vagy annak sóját tartalmazza, valamint atalálmány tárgya eljárás egy hiszton dezacetiláz inhibitoroktumorellenes hatásának kiértékelésére, ami legalább azt a lépésttartalmazza, hogy egy vizsgált sejtet egy hiszton dezacetilázinhibitorral kezelnek, és tartalmazza azt a lépést, hogy mérik egyspecifikus gén (vagy specifikus fehérje) expressziójának változását avizsgált sejtben, az említett inhibitorral végzett kezelés előtt ésután, majd összehasonlítják a két expressziós mennyiséget. Ó
HU0400668A 2001-08-21 2002-08-20 A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére HU229521B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001250846 2001-08-21
PCT/JP2002/008355 WO2003015810A1 (fr) 2001-08-21 2002-08-20 Usage medical d'un inhibiteur d'histone desacetylase et methode d'evaluation de son activite antitumorale

Publications (3)

Publication Number Publication Date
HUP0400668A2 true HUP0400668A2 (hu) 2005-01-28
HUP0400668A3 HUP0400668A3 (en) 2012-09-28
HU229521B1 HU229521B1 (hu) 2014-01-28

Family

ID=19079582

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400668A HU229521B1 (hu) 2001-08-21 2002-08-20 A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére

Country Status (14)

Country Link
US (1) US8470783B2 (hu)
EP (1) EP1426054B1 (hu)
JP (1) JP4238728B2 (hu)
AT (1) ATE526029T1 (hu)
CA (1) CA2457043A1 (hu)
DK (1) DK1426054T3 (hu)
ES (1) ES2371630T3 (hu)
HU (1) HU229521B1 (hu)
MX (1) MXPA04001612A (hu)
NO (1) NO331682B1 (hu)
PL (1) PL210794B1 (hu)
PT (1) PT1426054E (hu)
RU (1) RU2298414C2 (hu)
WO (1) WO2003015810A1 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009761A (es) * 2002-04-05 2005-05-27 Fujisawa Pharmaceutical Co Dipsipeptido para terapia de cancer renal.
JPWO2004074478A1 (ja) * 2003-02-19 2006-06-01 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
EP2238982B8 (en) 2003-06-27 2013-01-16 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
EP1713460A2 (en) * 2003-12-10 2006-10-25 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
EP1697538A1 (en) * 2003-12-18 2006-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Method for identifying histone deacetylase inhibitors
KR101167601B1 (ko) * 2004-02-25 2012-07-27 아스텔라스세이야쿠 가부시키가이샤 항종양제
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
JP2006000113A (ja) * 2004-05-20 2006-01-05 Masatomo Sakurai 漢方医療の診断に用いる遺伝子およびその利用方法
NZ599464A (en) 2005-02-03 2014-03-28 Topotarget Uk Ltd Combination therapies using hdac inhibitors
US7604939B2 (en) 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
JP5108750B2 (ja) 2005-05-13 2012-12-26 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤の医薬製剤
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
US20080292616A1 (en) * 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
EP1965824A4 (en) * 2005-11-18 2011-10-19 Gloucester Pharmaceuticals Inc METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228
US20100137239A1 (en) 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
DK2099442T3 (en) 2006-12-26 2015-02-16 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
CN101801994A (zh) 2006-12-29 2010-08-11 格洛斯特制药公司 制备Romidepsin
BRPI0720734A2 (pt) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
NZ579048A (en) 2007-01-30 2012-05-25 Pharmacyclics Inc Methods for determining cancer resistance to histone deacetylase inhibitors
MX2010003230A (es) 2007-09-25 2010-04-07 Topotarget Uk Ltd Metodos para la sintesis de ciertos compuestos de acido hidroxamico.
US20120190817A2 (en) * 2010-07-12 2012-07-26 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
JP3494624B2 (ja) * 1997-09-02 2004-02-09 住友製薬株式会社 新規な環状テトラペプチド誘導体とその医薬用途
WO1999022773A2 (en) * 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
EA007649B1 (ru) 1999-09-08 2006-12-29 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Ингибиторы гистондеацетилазы, вызывающие дифференцировку клеток, и их применение
CA2393682C (en) * 1999-12-08 2012-01-31 Xcyte Therapies, Inc. Depsipeptide and congeners thereof for use as immunosuppressants
CA2317003A1 (en) 2000-02-28 2001-08-28 Hidenori Nakajima Gene expression potentiator
JP2001348340A (ja) * 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
JP4810784B2 (ja) * 2000-07-17 2011-11-09 アステラス製薬株式会社 還元型ｆｋ２２８およびその用途
MXPA04009761A (es) * 2002-04-05 2005-05-27 Fujisawa Pharmaceutical Co Dipsipeptido para terapia de cancer renal.
EP2238982B8 (en) * 2003-06-27 2013-01-16 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
PL368708A1 (en) 2005-04-04
RU2004108137A (ru) 2005-05-10
PL210794B1 (pl) 2012-03-30
HU229521B1 (hu) 2014-01-28
MXPA04001612A (es) 2004-07-08
RU2298414C2 (ru) 2007-05-10
JP4238728B2 (ja) 2009-03-18
US8470783B2 (en) 2013-06-25
WO2003015810A1 (fr) 2003-02-27
EP1426054B1 (en) 2011-09-28
EP1426054A1 (en) 2004-06-09
NO20040731L (no) 2004-04-20
ES2371630T3 (es) 2012-01-05
ATE526029T1 (de) 2011-10-15
NO331682B1 (no) 2012-02-20
EP1426054A4 (en) 2006-09-13
HUP0400668A3 (en) 2012-09-28
PT1426054E (pt) 2011-12-06
DK1426054T3 (da) 2011-12-12
CA2457043A1 (en) 2003-02-27
JPWO2003015810A1 (ja) 2004-12-02
US20050191713A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
HUP0400668A2 (hu) A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
HUP0400719A2 (hu) Vegyületek és eljárások Chlamydia-fertőzés diagnosztikájára és kezelésére
MXPA04000080A (es) Metodos de diagnostico de cancer en la vejiga, composiciones y metodos de rastreo de moduladores de cancer en la vejiga.
HUP0202512A2 (hu) Fehérjék polimerizációját gátló anyagok és eljárások ezek alkalmazására
BRPI0415779A (pt) tratamento de doenças proliferativas usando um oligÈmero antisenso iap e um agente quimioterápico
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
NO20055838L (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
ATE350662T1 (de) Markerproteine für prostatakrebs
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
MXPA05008904A (es) Metodo para estimar el efecto antitumoral del inhibidor de desacetilasa de histona.
WO2006094068A3 (en) Hdac inhibitors that promote brm expression and brm related diagnostics
PT1233787E (pt) Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
YU16399A (sh) ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze
NO20053903L (no) Nukleotidlipidesterderivater.
WO2003106681A3 (de) Antisense oligonukleotide gegen pim1
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
WO2003035048A3 (en) Methods for the treatment of osteoarthritis and compositions thereof
DE602004030824D1 (de) An der oberfläche befindliche campylobacter jejuni-polypeptide
AU2003250912A1 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
AU2003293556A1 (en) Methods of diagnosing and treating cancer
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
WO2004034994A3 (en) Methods and compositions for determining risk of treatment toxicity
Adrianto et al. DNA adducts, genotoxicity mechanism of alkyl compounds in association with forensic dentistry

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ASTELLAS PHARMA INC., JP

Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP

MM4A Lapse of definitive patent protection due to non-payment of fees